Pharmaceutical composition containing honeysuckle extract and antibiotics, pharmaceutical kit, and use of honeysuckle extract for preparation of drug

Abstract

Provided is a pharmaceutical composition useful for prevention and/or treatment of diseases caused by bacteria, wherein the pharmaceutical composition comprising a honeysuckle extract containing iridoid compounds and an antibiotic. Also provided is a pharmaceutical kit comprising the honeysuckle extract containing the iridoid compounds and the antibiotics which are separately placed. The honeysuckle extract is used in combination with the antibiotics, the responsiveness of multi-drug resistant bacteria to antibiotics is improved, a clinical application prospect is presented, especially the current status of the refractory bacterial infection diseases caused by the pathogenic bacteria resistant to the antibiotics can be improved. Also provided is a use of the pharmaceutical composition and pharmaceutical kit in the preparation of drugs for prevention and/or treatment a diseases caused by bacteria. In addition, also provided is a use of the honeysuckle extract in the preparation of drugs for reversing bacterial resistance.

Claims

1. A pharmaceutical composition for preventing and/or treating a disease caused by a bacterium, comprising a honeysuckle extract containing iridoid compounds and an antibiotic; wherein the honeysuckle extract contains secologanic acid represented by the following structural formula (1): ##STR00003## wherein in formula (1), X.sub.1 and X.sub.2 each independently represent O, and R represents H; wherein the honeysuckle extract contains 50 wt % or more of secologanic acid represented by formula (1); wherein the preventing and/or treating a disease caused by a bacterium is achieved by reversing resistance of bacteria; wherein the antibiotic is ampicillin and/or erythromycin, and the antibiotic is greater in weight amount than that of the honeysuckle extract; and wherein the honeysuckle extract is prepared by a method comprising the following steps: (1) pulverizing honeysuckle (Lonicera japonica), and extracting the pulverized honeysuckle with water and/or C.sub.1-C.sub.6 alkyl alcohol aqueous solution containing not more than 95% alcohol by volume to obtain an extract; (2) concentrating the extract obtained in step (1) under normal or reduced pressure to obtain an extractum, or performing spray-drying on the extract obtained in step (1) to obtain a powder, and dissolving the extractum or powder with water, then carrying out precipitation or settlement with C.sub.1-C.sub.6 alkyl alcohol aqueous solution containing not more than 95% alcohol by volume to obtain a precipitate or a dissolving liquid concentrate; (3) isolating and purifying the precipitate or dissolving liquid concentrate obtained in step (2) by chromatography, and collecting eluent containing iridoid compounds, wherein the chromatography is selected from one or more of macroporous adsorption resin column chromatography, normal phase silica gel chromatography and reversed phase silica gel chromatography.

2. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and/or excipient.

3. A pharmaceutical kit for preventing and/or treating a disease caused by a bacterium, comprising a honeysuckle extract containing iridoid compounds and an antibiotic which are placed separately; wherein the honeysuckle extract contains secologanic acid represented by the following structural formula (1): ##STR00004## wherein, X.sub.1 and X.sub.2 each independently represent O, and R represents H; and wherein the honeysuckle extract contains 50 wt % or more of secologanic acid represented by formula (1), wherein preventing and/or treating a disease caused by a bacterium is achieved by reversing resistance of bacteria; wherein the antibiotic is ampicillin and/or erythromycin, and the antibiotic is greater in weight amount than that of the honeysuckle extract; and wherein the honeysuckle extract is prepared by a method comprising the following steps: (1) pulverizing honeysuckle (Lonicera japonica), and extracting the pulverized honeysuckle with water and/or C.sub.1-C.sub.6 alkyl alcohol aqueous solution containing not more than 95% alcohol by volume to obtain an extract; (2) concentrating the extract obtained in step (1) under normal or reduced pressure to obtain an extractum, or performing spray-drying on the extract obtained in step (1) to obtain a powder, and dissolving the extractum or powder with water, then carrying out precipitation or settlement with C.sub.1-C.sub.6 alkyl alcohol aqueous solution containing not more than 95% alcohol by volume to obtain a precipitate or a dissolving liquid concentrate; (3) isolating and purifying the precipitate or dissolving liquid concentrate obtained in step (2) by chromatography, and collecting eluent containing iridoid compounds, wherein the chromatography is selected from one or more of macroporous adsorption resin column chromatography, normal phase silica gel chromatography and reversed phase silica gel chromatography.

4. The pharmaceutical composition according to claim 1, wherein the honeysuckle extract contains 70 wt % or more of secologanic acid.

5. The pharmaceutical composition according to claim 1, wherein the honeysuckle extract contains 80 wt % or more of secologanic acid.

6. The pharmaceutical composition according to claim 1, wherein the honeysuckle extract contains 90 wt % or more of secologanic acid.

7. A method of treating a disease caused by a bacterium in a subject in need thereof comprising administering to the subject an effective amount of the pharmaceutical according to claim 1, wherein the bacterium is an ampicillin-resistant, erythromycin-resistant bacterium, and/or multiple antibiotic-resistant bacterium.

8. The method according to claim 7, wherein the bacterium is a gram-negative bacterium, and wherein gram-negative bacterium is an ampicillin-resistant Escherichia coli, Pseudomonas aeruginosa, and/or Klebsiella pneumoniae.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) Hereinafter, the examples of the present invention will be illustrated in detail in combination with the accompanying draws:

(2) FIG. 1 shows an HPLC chromatogram of honeysuckle extract N1 prepared in Example 1 according to the present invention, which was determined to contain 90.67% (by weight) of secologanic acid;

(3) FIG. 2 shows experimental results of improving sensitivity of Klebsiella pneumoniae to the antibiotic “ampicillin” by using the honeysuckle extract;

(4) FIG. 3 shows experimental results of improving sensitivity of Staphylococcus aureus to the antibiotic “erythromycin” by using the honeysuckle extract;

(5) FIG. 4 shows experimental results of improving sensitivity of Escherichia coli to the antibiotic “ampicillin” by using the honeysuckle extract;

(6) FIG. 5 shows experimental results of improving sensitivity of Pseudomona aeruginosa to the antibiotic “ampicillin” by using the honeysuckle extract;

(7) FIG. 6 shows an HPLC chromatogram of secologanic acid standard employed in the example of the present invention, with a purity of 98.03% (by weight).

DETAILED DESCRIPTION OF THE EMBODIMENTS

(8) The present invention will be further described in detail below in conjunction with the specific embodiments, and the examples provided are only intended to illustrate the present invention rather than limit the scope of the present invention.

(9) The experimental methods in the following examples are all conventional methods unless expressly stated. The experimental materials such as medicinal materials and reagent materials used in the following examples can be purchased from conventional biochemical reagent stores or pharmaceutical trading enterprises unless expressly stated. Wherein:

(10) Honeysuckle herbs employed in the examples were purchased from Beijing Tongrentang chain drug stores, produced in the province of Henan, and processed by Bozhou City Beijing Anhui Chinese Medicine Yinpian Factory, with lot number of 200502014. The honeysuckle herbs were identified as dried buds of Lonicera japonica Thunb. of caprifoliaceae by Institute of Materia Medica, Chinese Academy of Medical Sciences.

(11) The secologanic acid used in the examples, as the standard for determining the content of the extract, is prepared according to the method disclosed in the patent ZL200610083556.7 by Research Department of Natural Medicinal Chemistry of Institute of Materia Medica, Chinese Academy of Medical Sciences. Though measurement, the content is determined to be 98.03% (the chromatogram is shown in FIG. 6).

(12) In the examples, the content of the secologanic acid in the honeysuckle extract is determined according to the HPLC external standard method, and specifically, the following instruments and conditions are employed for measurement:

(13) (1) Instrument: Agilent 1100 liquid chromatograph including quaternary pump, autosampler, DAD detector and Chemstation chromatography workstation;

(14) (2) Chromatographic conditions and system suitability test: the chromatographic column is Prevail C.sub.18 5μ (250 mm×4.6 mm) [Alltech, USA]; acetonitrile-1% glacial acetic acid aqueous solution (13:87) is used as the mobile phase, gradient elution is employed; the flow rate is 0.9 ml/min, the stopping time is 40 minutes, the equilibrium time is 10 minutes and the detection wavelength is 242 nm. The number of theoretical plates calculated by JYH peak should be no less than 1000.

(15) (3) Reagents: acetonitrile gradient grade for chromatography; pure water; analytical grade acetic acid.

(16) The bacteria of Escherichia coli, Pseudomona aeruginosa, Klebsiella pneumonia and Staphylococcus aureus used in the examples are all clinical isolates (multiple resistant bacteria), which were provided by the clinical laboratory of the Fourth People's Hospital of Jinan in Shandong province, the resistances of the bacteria are shown in the tables 1, 2, 3, 4 and 5 below.

(17) TABLE-US-00001 TABLE 1 Background materials of Klebsiella pneumoniae Number Date Kind of of of specimen Department specimen specimen AMP PIP TZP AMC CZO CXM CTX CAZ CRO IPM 31853 Internal 2010- urine R I S S S S S S S S medicine 3 10-29 FEP FOX GEN AMK CIP CHL SXT TCY NIT S S S S R I R R R

(18) TABLE-US-00002 TABLE 2 Background materials of Escherichia coli Number Date Kind of of of specimen Department specimen specimen AMP PIP TZP AMC CZO CXM CTX CAZ CRO IPM 32042 Internal 2010- urine R R I I R R R R R S medicine 6 10-29 FEP FOX GEN AMK CIP CHL SXT TCY NIT R R R S R S R R R Notes of Table 1 and Table 2: R: Resistant; S: Sensitive; I: Intermediate degree (moderate resistance). AMP: ampicillin; PIP: piperacillin; TZP: piperacillin/tazobactam; AMC: amoxicillin/clavulanic acid; CZO: cefazolin; CXM: cefuroxime; CTX: cefotaxime; CAZ: ceftazidime; CRO: ceftriaxone; IPM: imipenem; FEP: cefepime; FOX: cefoxitin; GEN: gentamicin; AMK: amikacin; CIP: ciprofloxacin; CHL: chloramphenicol; SXT: trimethoprim-sulfamethoxazole; TCY: tetracycline; NIT: nitrofurantoin.

(19) TABLE-US-00003 TABLE 3 Background materials of Pseudomona aeruginosa Number of Date of specimen specimen AK ATM AMP CRO CLS CXM CAZ CTX CFP CIP CN 12 2007-3 S S R R S R S S S S S FEP LEV NOR PIP SAM TIM TOB TZP IPM MH S S S S R S S S S R Notes: R: Resistant; S: Sensitive; I: Intermediate degree. AK: amikacin; ATM: aztreonam; AMP: ampicillin; CRO: ceftriaxone; CLS: sulperazon; CXM: cefuroxime sodium; CAZ: ceftazidime; CTX: cefotaxime; CFP: cefoperazone; CIP: ciprofloxacin; CN: gentamicin; FEP: cefepime; LEV: left-handed oxygen fluorine; NOR: norfloxacin; PIP: piperacillin; SAM: ampicillin/sulbactam; TIM: ticarcillin/clavulanic acid; TOB: tobramycin; TZP: tazocin; IPM: imipenem; MH: minocycline; MEM: meropenem.

(20) TABLE-US-00004 TABLE 4 Background materials of Staphylococcus aureus Number Kind of Date of of specimen Department specimen specimen PNE OXA SAM FOX GEN AMK CIP Y31692 Surgery 4 2010-10-1 secretion R S S S S S S ERY VAN RIF SXT TCY CLI NIT R S S S R R S Notes: R: Resistant; S: Sensitive; I: Intermediate degree. PEN: penicillin; OXA: oxacillin; SAM: ampicillin/penam sulfone; FOX: cefoxitin; GEN: gentamicin; AMK: amikacin; CIP: ciprofloxacin; ERY: erythromycin; VAN: vancomycin; RIF: rifampin; SXT: trimethoprim-sulfamethoxazole; TCY: tetracycline; CLI: clindamycin; NIT: nitrofurantoin.

(21) Culture medium: MH broth.

(22) Equipments Employed in the Examples:

(23) Constant temperature incubator: product of Shanghai Yuejin Medical Device Factory 1.

(24) Clean bench: product of Jinan Longhong Corporation.

(25) Microplate reader: product of Finland Leibo Corporation.

(26) 722 spectrophotometer: product of Shanghai Precision & Scientific Instrument Co., Ltd.

(27) −80° C. refrigerator: product of American FOMAS Corporation.

Example 1 Preparation of Honeysuckle Extract

(28) Honeysuckle herbs (500 g) were taken, pulverized coarsely, and extracted twice with 50% (v/v) ethanol aqueous solution which is 13 times the dry weight of honeysuckle herbs, each extraction was performed for 1 hour. The extracts were combined, and concentrated under reduced pressure to obtain a thick extractum, then the extractum was added with 450 ml distilled water and dissolved by heating, then cooled to room temperature, left to stand for 24 hours and filtered to obtain a clear solution.

(29) The clear solution was concentrated under reduced pressure to dryness, and added with 1600 ml of 95% (v/v) ethanol aqueous solution, and stirred sufficiently to be dissolved, and also the solution was slowly added with distilled water to make it contain 75% (v/v) ethanol, then left to stand for 24 hours and filtered to collect the filtrate, then ethanol was recovered from the filtrate under reduced pressure until the fluid extractum was formed.

(30) The fluid extractum was added with 500 ml water, dissolved and filtered, then the filtrate was passed through the pretreated SP-825 styrene macroporous adsorption resin chromatographic column, and the column was eluted sequentially with 5 times the amount of the resin column volumes of water and 6 times the amount of the resin column volumes of 20% (v/v) ethanol aqueous solution, and then ethanol was recovered from the eluent under reduced pressure, until there was no alcohol flavor, and freeze-drying was performed.

(31) Further purification was performed using Sephadex LH-20 gel chromatographic column, comprising: eluting with water, collecting the sample liquid, recovering under reduced pressure, and performing freeze-drying; and the purification was performed several times through the gel chromatographic column to obtain the honeysuckle extract N1. The honeysuckle extract N1 was determined to contain 90.67% secologanic acid according to the HPLC external standard method by using secologanic acid as the reference object (the chromatogram is shown in FIG. 1).

Example 2 Bacterial Inhibition Test of Antibiotics

(32) In this example, bacterial inhibition effects of antibiotics on the four multiple resistant bacteria in Tables 1-4 were measured.

(33) The activated bacterium suspension was diluted to a concentration equivalent to 0.5 McFarland turbidity standard, and diluted with the culture medium of MH broth in a proportion of 1:1000, and then added into each well in amount of 100 μL per well.

(34) The antibiotics resisted by the above four multiple resistant bacteria were diluted to 1:2048 (2.sup.−11) from 1 mg/mL (initial concentration) by 2-fold dilution, and then the original solution and different concentrations of diluted antibiotics were added respectively into the well containing the bacterium suspension, with each well added with 100 μL, and the minimum inhibitory concentration (MIC) of each antibiotic was recorded finally.

(35) Meanwhile, a bacterium solution control (that is, bacterium solution plus an equal volume of culture medium) and a blank culture medium control were set.

(36) Cultivation was performed at 37° C. for 20 h, and detection was performed at 630 nm by the microplate reader, and the bacterial inhibition rate is calculated according to formula {circle around (2)}, and the data obtained is put into formula {circle around (1)} to calculate specific distance, and the specific distance is added to the virus dilution index with pathologic rate less than 50% to obtain half inhibitory concentration (Reed-Muench method).
Specific distance=(inhibition rate of greater than 50%−50%)/(inhibition rate of greater than 50%−inhibition rate of less than 50%)  formula {circle around (1)}
Inhibition rate=(bacterial inhibition test OD value−drug control OD value)/(bacterium solution control OD value−blank control OD value)  formula {circle around (2)}

(37) The results show that, as to the antibiotics resisted by the above four bacteria, except the antibiotic of ampicillin resisted by Klebsiella pneumonia, which has inhibitory effect on Klebsiella pneumoniae in the first two dilutions (1 mg/mL, 0.5 mg/mL), all of antibiotics resisted by the four bacteria in each dilution are resisted by the bacteria.

Example 3 Research on Antibacterial Effect of the Pharmaceutical Composition of the Present Invention

(38) The experiment of combined effects of the following antibiotics and honeysuckle extract N1 on bacteria were carried out:

(39) TABLE-US-00005 TABLE 5 Bacteria and antibiotics for the experiment of combined effects Bacteria Antibiotics Klebsiella pneumoniae ampicillin Staphylococcus aureus erythromycin Escherichia coli ampicillin Pseudomona aeruginosa ampicillin

(40) The antibiotics in Table 5 were diluted to 2.sup.−5 from 1 mg/mL (initial concentration) by 2-fold dilution, and then added into the 96-well plate successively in transverse direction in amount of 100 μl per well. The antibiotic of each dilution was added into three wells. The test sample of honeysuckle extract N1 prepared in Example 1 was diluted with PBS to a concentration of 40 mg/ml, and then diluted by 2-fold serial dilution (1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128), followed by added into each well in amount of 100 μl per well.

(41) Meanwhile, an antibiotic control (replacing honeysuckle extract N1 with blank culture medium), bacterium solution control and blank culture medium control were set.

(42) Cultivation was performed at 37° C. for 20 h, and the absorbance was detected at 600 nm by a spectrophotometer.

(43) The results are shown in FIG. 2 to FIG. 5, wherein the antibiotic in each figure was diluted to 2.sup.−5 from 1 mg/mL (initial concentration) by 2-fold dilution, therefore the abscissas 1-6 in each figure represent the concentrations of 2.sup.−1-2.sup.−5 respectively. It can be seen from the results of the figures that, addition of the honeysuckle extract significantly enhances the sensitivity of four multiple resistant bacteria to the corresponding antibiotics, therefore the honeysuckle extract can be made into the pharmaceutical composition by mixing with the antibiotic or be administered in combination with the antibiotic, so as to be used for prevention and/or treatment of diseases caused by resistant bacteria.

Example 4 Preparation of Honeysuckle Extract and Honeysuckle Water Decoction

(44) The honeysuckle extracts with different contents of secologanic acid and honeysuckle water decoction were prepared in this example.

(45) (1) Preparation of Honeysuckle Extract

(46) Honeysuckle herbs (500 g) were taken, pulverized coarsely, and extracted twice with 50% (v/v) ethanol aqueous solution which is 13 times the dry weight of honeysuckle herbs, each extraction was performed for 1 hour. The extracts were combined, and concentrated under reduced pressure to obtain a thick extractum, then the extractum was added with 450 ml distilled water and dissolved by heating, then cooled to room temperature, left to stand for 24 hours and filtered to obtain a clear solution.

(47) The clear solution was concentrated under reduced pressure to dryness, and added with 1600 ml of 95% (v/v) ethanol aqueous solution, and stirred sufficiently to be dissolved, and also the solution was slowly added with distilled water to make it contain 75% (v/v) ethanol, then left to stand for 24 hours and filtered to collect the filtrate, then ethanol was recovered from the filtrate under reduced pressure until the fluid extractum was formed.

(48) The fluid extractum was added with 500 ml water, dissolved and filtered, then the filtrate was passed through the pretreated SP-825 styrene macroporous adsorption resin chromatographic column, and the column was eluted sequentially with 5 times the amount of the resin column volumes of water and 6 times the amount of the resin column volumes of 20% (v/v) ethanol aqueous solution, and then ethanol was recovered from the eluent under reduced pressure, until there was no alcohol flavor, and freeze-drying was performed to obtain 4.31 g honeysuckle extract (honeysuckle extract N4).

(49) The honeysuckle extract N4 was determined to contain 52% secologanic acid according to the HPLC external standard method by using secologanic acid as the reference (the chromatogram is shown in FIG. 7).

(50) The honeysuckle extract N4 was further purified using the Sephadex LH-20 gel chromatographic column, comprising: eluting with water, collecting the sample liquid, recovering under reduced pressure, and performing freeze-drying; and the resulting product was purified several times through the gel chromatographic column to obtain the honeysuckle extracts N3 (2.80 g, which contains 79.3% secologanic acid with chromatogram shown in FIG. 8), N2 (2.55 g, which contains 84.7% secologanic acid, with chromatogram shown in FIG. 9) and N1 (2.40 g, which contains 90.67% secologanic acid, with chromatogram shown in FIG. 10) respectively. The above concentrations were measured according to the HPLC external standard method by using secologanic acid as the reference.

(51) (2) Preparation of Honeysuckle Water Decoction

(52) Honeysuckle herbs (500 g) were taken, pulverized, and added with 5000 ml water, and decocted in the water, until the herb solution was evaporated to 500 ml, so that 1 g/ml crude drug was contained in the herb solution which was named honeysuckle water decoction W.

Example 5 Research on Antibacterial Effects of the Honeysuckle Extracts N1 to N4 and Honeysuckle Water Decoction W Prepared by the Present Invention which are Respectively Combined with Antibiotics

(53) This example studies the antimicrobial effects in vivo of the honeysuckle extracts N1 to N4 which are respectively combined with antibiotics, and the antimicrobial effects were compared with that of the honeysuckle water decoction W combined with the antibiotic.

(54) The experimental strain is Klebsiella pneumoniae which was isolated from the sputum specimen of the patient in the ward of the Fourth People's Hospital of Jinan in 2010, and detection of the drug resistant spectrum is shown in Table 6 below.

(55) TABLE-US-00006 TABLE 6 Drug resistant spectrum of the experimental strain of Klebsiella pneumoniae Number Date Kind of of of specimen Department specimen specimen AMP PIP TZP AMC CZO CXM CTX CAZ CRO IPM 31494 Surgery 6 2010- Sputum R R I I R R R S R S 10-11 FEP FOX GEN AMK CIP CHL SXT TCY NIT S S R S R R R R R Notes: R: Resistant; S: Sensitive; I: Intermediate degree (moderate resistance). AMP: ampicillin; PIP: piperacillin; TZP: piperacillin/tazobactam; AMC: amoxicillin/clavulanic acid; CZO: cefazolin; CXM: cefuroxime; CTX: cefotaxime; CAZ: ceftazidime; IPM: imipenem; FEP: cefepime; FOX: cefoxitin; GEN: gentamicin; AMK: amikacin; CIP: ciprofloxacin; CHL: chloramphenicol; SXT: trimethoprim-sulfamethoxazole; TCY: tetracycline; NIT: nitrofurantoin.

(56) The control strain is clinically isolated AMP-sensitive strain, which was isolated from the sputum specimen of the patient in the ward of the Fourth People's Hospital of Jinan in 2010, and preserved until today.

(57) KM mice were purchased from the Experimental Animal Center of Shandong University, weighing 16-18 g, with half male and half female and animal license number of SCXK (Lu) 20090001.

(58) Grouping of Animals:

(59) There were 5 control groups with 10 mice in each group: normal control group, AMP-sensitive bacterium quality control model control group (AMPS) and the treatment group thereof, AMP-resistant bacterium model control group (AMPR) and the treatment group thereof;

(60) There were 15 experimental groups with 10 mice in each group: N1 to N4 and W were respectively combined with AMP high-dose group, AMP medium-dose group and AMP low-dose group. Doses of administration are shown in Table 7 below.

(61) TABLE-US-00007 TABLE 7 Administration conditions and doses of animals in each group (n = 10) Groups Dose of administration (per mouse) Normal control group Sterile normal saline AMP-sensitive bacterium infection model Sterile normal saline control group AMP-sensitive bacterium infection AMP 16.80 mg model-AMP intervention control group (quality control) AMP-resistant bacterium infection model Sterile normal saline control group AMP-resistant bacterium infection AMP 16.80 mg model-AMP intervention control group N1-AMP high-dose group 16.80 mg ampicillin sodium + 0.80 mg N1 N1-AMP medium-dose group 16.80 mg ampicillin sodium + 0.45 mg N1 N1-AMP low-dose group 16.80 mg ampicillin sodium + 0.10 mg N1 N2-AMP high-dose group 16.80 mg ampicillin sodium + 0.80 mg N2 N2-AMP medium-dose group 16.80 mg ampicillin sodium + 0.45 mg N2 N2-AMP low-dose group 16.80 mg ampicillin sodium + 0.10 mg N2 N3-AMP high-dose group 16.80 mg ampicillin sodium + 0.80 mg N3 N3-AMP medium-dose group 16.80 mg ampicillin sodium + 0.45 mg N3 N3-AMP low-dose group 16.80 mg ampicillin sodium + 0.10 mg N3 N4-AMP high-dose group 16.80 mg ampicillin sodium + 0.80 mg N4 (equal to 93 mg crude drug in whole) N4-AMP medium-dose group 16.80 mg ampicillin sodium + 0.45 mg N4 (equal to 52 mg crude drug in whole) N4-AMP low-dose group 16.80 mg ampicillin sodium + 0.10 mg N4 (equal to 12 mg crude drug in whole) W-AMP high-dose group 16.80 mg ampicillin sodium + 0.093 ml W (equal to 93 mg crude drug in whole) W-AMP medium-dose group 16.80 mg ampicillin sodium + 0.052 ml W (equal to 52 mg crude drug in whole) W-AMP low-dose group 16.80 mg ampicillin sodium + 0.012 ml W (equal to 12 mg crude drug in whole)

(62) After being grouped, the animals were injected intraperitoneally with 2.5×10.sup.7 (Klebsiella pneumoniae)*100 μL.sup.−1 per animal, then immediately treated by administration, and the route of administration alternated between tail intravenous injection and intraperitoneal injection (the sterile normal saline was used as the solvent for drugs except W, since continuous tail intravenous injection causes damage to tail veins, therefore the tail intravenous injection and intraperitoneal injection were performed alternatively), the animal was injected once a day for 5 days continuously. The efficacy of each group was evaluated according to the animal mortality and intraperitoneal bacterial count.

(63) Results of Experiment:

(64) 1: Mortalities of the Animals are Shown in Table 8 Below.

(65) TABLE-US-00008 TABLE 8 Death condition of animals in each group Number of deaths 1.sup.st day 2.sup.nd day 3.sup.rd day 4.sup.th day 5.sup.th day Total Mortality (%) Normal control group 0 0 0 0 0 0 0 AMP-resistant bacterium 0 9 0 0 0 9 90 infection model control group AMP-resistant bacterium 0 7 2 1 0 10 100 infection model-AMP intervention control group AMP-sensitive bacterium 0 9 1 0 0 10 100 infection model control group AMP-sensitive bacterium 0 0 0 0 0 0 0 infection model-AMP intervention control group N1-AMP high-dose group 0 0 1 0 0 1 10 N1-AMP medium-dose 0 0 0 0 0 0 0 group N1-AMP low-dose group 0 4 1 0 0 5 50 N2-AMP high-dose group 0 1 1 0 0 2 20 N2-AMP medium-dose 0 2 0 0 0 2 20 group N2-AMP low-dose group 0 4 1 0 0 5 50 N3-AMP high-dose group 0 1 2 0 0 3 30 N3-AMP medium-dose 0 2 1 0 0 3 30 group N3-AMP low-dose group 0 4 2 0 0 6 60 N4-AMP high-dose group 0 2 1 0 0 3 30 N4-AMP medium-dose 0 2 1 0 0 3 30 group N4-AMP low-dose group 0 5 3 0 0 8 80 W-AMP high-dose group 0 4 4 0 0 8 80 W-AMP medium-dose 0 4 4 1 0 9 90 group W-AMP low-dose group 0 4 5 0 0 9 90

(66) Analysis on results of Table 3: as can be seen from Table 3, mortalities of animals in the AMP-resistant bacterium infection model control group and AMP-sensitive bacterium infection model control group are above 90%, indicating that the models are constructed successfully. Meanwhile, the animals in the AMP-sensitive bacterium infection model-AMP intervention control group are protected effectively, while the animals in the AMP-resistant bacterium infection model-AMP intervention control group cannot be protected (all of animals died), indicating that the experimental system was normal.

(67) As can be seen from the above results, when N1 to N4 and W were used in combination with AMP, N1 to N4 can effectively enable the animals of the experimental AMP-resistant bacterium infection model to avoid death, indicating that the test sample changes the sensitivity of experimental bacteria to antibiotics, wherein N1 has the most prominent effect. In contrast, combination of W and AMP has the worst effect, with high mortality of model animals, therefore substantially having no effect of changing sensitivity of bacteria to antibiotics.

(68) 2: Intraperitoneal Colony Counting of Animals

(69) Intraperitoneal bacterium counting of dead animals: the animals were injected intraperitoneally with 1 ml sterile normal saline immediately after they died, and the abdomens of the animals were kneaded gently for 1 min, the ascites was drawn and coated on the plate after gradient dilution, and cultured at 37° C. overnight, then the colonies were counted;

(70) Intraperitoneal bacterium counting of surviving animals: the mice were administrated continuously for 5 days and sacrificed through dislocation 2 h after the last administration, then the mice were injected intraperitoneally with 1 ml sterile normal saline, and the abdomens of the mice were kneaded gently for 1 min, the ascites was drawn and coated on the plate after gradient dilution, and cultured at 37° C. overnight, then the colonies were counted, colony count results of the control groups are shown in table 9 below, and colony count results of the experimental groups are shown in table 10 below.

(71) TABLE-US-00009 TABLE 9 Intraperitoneal colony count of animals Groups AMP-sensitive AMP-resistant bacterium AMP-resistant bacterium AMP-sensitive (AMPS) bacterium (AMPR) bacterium infection (AMPR) infection (AMPS) model-AMP infection model-AMP Normal infection model intervention model control intervention Nos. control group control group control group group control group 1 0 3.774 × 10.sup.10 1.054 × 10.sup.1 3.450 × 10.sup.10 3.557 × 10.sup.10 2 0 3.105 × 10.sup.10 0 3.300 × 10.sup.10 3.478 × 10.sup.10 3 0 4.086 × 10.sup.10 0 3.537 × 10.sup.10 3.578 × 10.sup.10 4 0 3.948 × 10.sup.10 0 3.483 × 10.sup.10 3.487 × 10.sup.10 5 0 3.511 × 10.sup.10 0 3.300 × 10.sup.10 3.550 × 10.sup.10 6 0 9.560 × 10.sup.9  0 3.375 × 10.sup.10 3.373 × 10.sup.10 7 0 8.994 × 10.sup.9  0 7.667 × 10.sup.9  3.360 × 10.sup.10 8 0 4.258 × 10.sup.9  0 9.833 × 10.sup.9  6.617 × 10.sup.9  9 0 7.220 × 10.sup.9  0 5.950 × 10.sup.9  4.800 × 10.sup.9  10  0 6.614 × 10.sup.9  0 6.500 × 10.sup.3  5.467 × 10.sup.9  Bacterium 0 100 10  100 100 isolation positive rate (%)

(72) As can be seen from Table 9, the mouse infection model of the ampicillin-sensitive bacteria is sensitive to ampicillin, while the mouse infection model of the resistant bacteria cannot be controlled by ampicillin, and experimental system is normal.

(73) TABLE-US-00010 TABLE 10 Intraperitoneal colony count of animals Groups N1-AMP N1-AMP N1-AMP N2-AMP N2-AMP N2-AMP high-dose medium-dose low-dose high-dose medium-dose low-dose Nos. group group group group group group 1 6.480 × 10.sup.9 0 2.327 × 10.sup.10 6.480 × 10.sup.9 7.349 × 10.sup.9 1.394 × 10.sup.10 2 0 0 2.475 × 10.sup.10 7.167 × 10.sup.9 6.191 × 10.sup.3 2.652 × 10.sup.10 3 0 0 5.143 × 10.sup.9  6.341 × 10.sup.3 5.276 × 10.sup.2 9.226 × 10.sup.9  4 0 0 5.312 × 10.sup.9  0 6.217 × 10.sup.2 8.958 × 10.sup.8  5 0 0 6.133 × 10.sup.8  0 0 1.239 × 10.sup.9  6 0 0 4.333 × 10.sup.2  0 0 6.240 × 10.sup.2  7 0 0 8.833 × 10.sup.1  0 0 0 8 0 0 0 0 0 0 9 0 0 0 0 0 0 10  0 0 2 0 0 0 Bacterium 20  0 70  30  40  60  isolation positive rate (%) Groups N3-AMP N3-AMP N3-AMP N4-AMP N4-AMP N4-AMP W-AMP W-AMP W-AMP high-dose medium-dose low-dose high-dose medium-dose low-dose high-dose medium-dose low-dose Nos. group group group group group group group group group 1 6.361 × 10.sup.9  2.677 × 10.sup.10 3.739 × 10.sup.10 5.221 × 10.sup.9  3.259 × 10.sup.10 9.773 × 10.sup.9  3.694 × 10.sup.10 3.609 × 10.sup.10 2 1.165 × 10.sup.10 3.534 × 10.sup.10 3.841 × 10.sup.10 1.478 × 10.sup.10 2.299 × 10.sup.10 3.916 × 10.sup.10 2.340 × 10.sup.10 3.715 × 10.sup.10 3.480 × 10.sup.10 3 9.330 × 10.sup.9  7.992 × 10.sup.8  9.215 × 10.sup.9  2.468 × 10.sup.10 4.761 × 10.sup.10 1.643 × 10.sup.10 8.216 × 10.sup.9  3.829 × 10.sup.10 8.641 × 10.sup.9  4 8.062 × 10.sup.3  6.749 × 10.sup.3  7.117 × 10.sup.8  1.635 × 10.sup.4  8.330 × 10.sup.3  8.894 × 10.sup.9  2.331 × 10.sup.9  4.057 × 10.sup.10 5.099 × 10.sup.9  5 7.694 × 10.sup.2  8.357 × 10.sup.2  6.286 × 10.sup.7  7.239 × 10.sup.2  1.299 × 10.sup.3  1.831 × 10.sup.10 4.942 × 10.sup.7  2.348 × 10.sup.7  1.587 × 10.sup.10 6 0 5.383 × 10.sup.3  5.445 × 10.sup.8  0 2.074 × 10.sup.2  1.285 × 10.sup.10 7.259 × 10.sup.5  4.206 × 10.sup.4  1.405 × 10.sup.9  7 0 4.156 × 10.sup.2  1.299 × 10.sup.4  0 5.62 × 10.sup.2  6.795 × 10.sup.9  6.320 × 10.sup.4  8.241 × 10.sup.3  1.823 × 10.sup.8  8 0 0 6.214 × 10.sup.2  0 0 5.318 × 10.sup.7  5.867 × 10.sup.3  7.542 × 10.sup.3  7.771 × 10.sup.7  9 0 0 0 0 0 7.358 × 10.sup.3  0 3.111 × 10.sup.2  6.282 × 10.sup.2  10  0 0 0 0 0 0 0 0 1.326 × 10.sup.2  Bacterium 50  70  80  50  70  90  90  90  100  isolation positive rate (%) Note: values in the table are the average of the ascitic colony counts of each mouse, in a unit of CFU/mL.

(74) It can be seen from the results of animal intraperitoneal colony count in Table 5 that, use of N1 to N4 and W in combination with ampicillin can control the ampicillin-resistant bacteria to different extents. When used in combination with AMP, N1 has the best effect and W has the worst effect. Dose-effect analysis shows that low dose has the poor effect, and there is no significant difference in effect between the medium-dose group and high-dose group.

(75) Considering the data of animal death and animal intraperitoneal bacterial count together as a whole, control groups (that is, normal control group, AMP-resistant bacterium infection model control group and AMP intervention control group thereof, AMP-sensitive bacterium infection model control group and AMP intervention control group thereof) were designed as a quality control system in the experiment, mortalities of animals in the model control group are above 90%, indicating that the model is constructed successfully. Meanwhile, the animals of the AMP-sensitive bacterium infection model were protected effectively, while the animals in the AMP-resistant bacterium infection model-AMP intervention control group cannot be protected, indicating that the experimental system is normal.

(76) The experiment analyzes the therapeutic effect of AMP in combination with N1 to N4 and W mainly through the data of animal death and bacterial count, the data show that, when N1 to N4 and W are used in combination with AMP, N1 to N4 can effectively protect the animals of the experimental AMP-resistant bacterium infection model from death, indicating that the test sample changes the sensitivity of the experimental bacteria to antibiotics, wherein N1 has the most prominent effect, and N4 has the worst effect, which indicates that the content of the secologanic acid in the honeysuckle extract has significantly positive correlation with the effect; Meanwhile, the experiment exhibits a good dose-effect relationship, that is, the effect of high-dose and medium-dose is significantly better than that of low-dose. Although W also shows a certain effect, the effect is significantly inferior to that of the extract.